Education Center Search
Found Posts: 65
Search Publications
Research Priorities for Heart Failure with Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary
This is a summary of a recent NIH Workshop that provides an extensive review of HFpEF, which is considered a disease with the highest unmet need in cardiovascular disease. This provides insight into the disease and a forecast of future initiatives to address the need to better understand the disease and to explore promising therapies.
Citation
Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R, Chirinos JA, Collins S, Deo RC, Gladwin MT, Granzier H, Hummel SL, Kass DA, Redfield MM, Sam F, Wang TJ, Desvigne-Nickens P, Adhikari BB. Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary. Circulation. 2020 Mar 24;141(12):1001-1026Source: https://pubmed.ncbi.nlm.nih.gov/32202936/
Developing Therapies for Heart Failure with Preserved Ejection Fraction: Current State and Future Directions
This is a summary of an FDA sponsored meeting that included academia, regulatory and industry to address the growing problem of HFpEF that currently has no identified effective treatment. This provides insight towards how the development of novel treatment will likely proceed.
Citation
Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O'Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014 Apr;2(2):97-112.Source: https://pubmed.ncbi.nlm.nih.gov/24720916/
Levosimendan in Acute and Advanced Heart Failure: an Appraisal of the Clinical Database and Evaluation of its Therapeutic Applications
This provides a summary of the use of levosimendan as an inotropic treatment of advanced heart failure from academic experts with firsthand knowledge and experience. Discussions include the relative safety of levosimendan compared to other inotropic drugs, and the chronic use in advanced disease.
Citation
Altenberger J, Gustafsson F, Harjola VP, Karason K, Kindgen-Milles D, Kivikko M, Malfatto G, Papp Z, Parissis J, Pollesello P, Pölzl G, Tschöpe C. Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. J Cardiovasc Pharmacol. 2018 Mar;71(3):129-136.Source: https://pubmed.ncbi.nlm.nih.gov/28817484/
Levosimendan Efficacy and Safety: 20 Years Of Simdax in Clinical Use
An extensive review of the 20 year experience of levosimendan in Europe, covering the indicated application for use in ADHF and the experience in a multitude of other clinical situations. This is a great reference paper that covers the broad scope of preclinical and clinical features of levosimendan.
Citation
Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, Černý V, Comin-Colet J, Crespo-Leiro MG, Delgado JF, Édes I, Eremenko AA, Farmakis D, Fedele F, Fonseca C, Fruhwald S, Girardis M, Guarracino F, Harjola VP, Heringlake M, Herpain A, Heunks LMA, Husebye T, Ivancan V, Karason K, Kaul S, Kivikko M, Kubica J, Masip J, Matskeplishvili S, Mebazaa A, Nieminen MS, Oliva F, Papp JG, Parissis J, Parkhomenko A, Põder P, Pölzl G, Reinecke A, Ricksten SE, Riha H, Rudiger A, Sarapohja T, Schwinger RHG, Toller W, Tritapepe L, Tschöpe C, Wikström G, Lewinski DV, Vrtovec B, Pollesello P. Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. J Cardiovasc Pharmacol. 2020 Jul;76(1):4-22.Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374352/
Oral Levosimendan in Patients with Severe Chronic Heart Failure --the Persist Study
This is a report of a randomized clinical trial of oral levosimendan as a chronic treatment for HFrEF. 300 patients were included in the trial which lasted 6 months. The primary endpoint, which was not achieved, was a novel composite that included symptoms and mortality. The secondary endpoints of NT-proBNP and patient questionnaire were achieved. Serious adverse events were not encountered.
Citation
Nieminen MS, Cleland JG, Eha J, Belenkov Y, Kivikko M, Põder P, Sarapohja T. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study. Eur J Heart Fail. 2008 Dec;10(12):1246-54.Source: https://pubmed.ncbi.nlm.nih.gov/18945637/
Pharmacotherapy in Pulmonary Arterial Hypertension: A Systemic Review and Meta-Analysis
Unbiased meta-analysis of the approved pulmonary vasodilator therapies for PAH. The authors improved upon two previous meta-analyses by addressing some of the limitations in those analyses. By pooling the available literature, they sought to determine the effect of the classes of medication on total mortality and secondarily to assess their impact on other clinical endpoints, including dyspnea, exercise tolerance, hemodynamics, and adverse effects
Citation
Ryerson CJ, Nayar S, Swiston JR, Sin DD. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res. 2010 Jan 29;11(1):12.Source: https://pubmed.ncbi.nlm.nih.gov/20113497/
Pulmonary Arterial Hypertension: Pathogenesis and Clinical Management
An outstanding and comprehensive review of PAH by experts in the field. This review summarizes the epidemiology, diagnostic evaluation, and treatment of PAH. It also examines recent advances in basic science, noting potential therapeutic targets and future research questions.
Citation
Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018 Mar 14;360:j5492.Source: https://pubmed.ncbi.nlm.nih.gov/29540357/
Modern Age Pathology of Pulmonary Arterial Hypertension
Authoritative review of the pathology of PAH, with a focus on the impact of modern treatments by leading experts. They show that in patients with advanced disease there is a distinct spectrum of pulmonary vascular and nonvascular pathologies, including localized interstitial and perivascular inflammation. In this set of patients who were being treated with the modern drug therapies, the appearance of classical pulmonary vascular lesions related to the disease was unaffected.
Citation
Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, Tuder RM. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012 Aug 1;186(3):261-72.Source: https://pubmed.ncbi.nlm.nih.gov/22679007/
Enhancing Insights into Pulmonary Vascular Disease Through a Precision Medicine Approach
NIH Workshop Summary from leading experts. A review of precision medicine approaches to treatments for PAH including inadequacies of therapy of PAH using the traditional approach, considerations in the conduct of clinical trials for a precision medicine approach, considerations in the design of clinical trials, and pharmaceutical industry challenges with precision medicine clinical trials.
Citation
Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, et. Al. Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670.Source: https://pubmed.ncbi.nlm.nih.gov/28430547/
Targeting of Platlet-Derived Growth Factor Signaling in Pulmonary Arterial Hypertension
Detailed review of the role of PDGF in PAH. The authors provide solid evidence that inhibition of PDGFR signaling by imatinib mesylate represents an encouraging therapeutic concept and is likely to become an additional targeted therapy for PAH. In addition to existing therapies, this anti-proliferative approach has the potential to establish a sustained reduction of the underlying pulmonary vascular remodeling.
